Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential ... This has caused its market value to fall to $2.2 billion, raising concerns about the company's financial stability.

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Shares of Bausch Health, Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO ... from $2.09 to $2.38.

It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products.

This compares to the stock's 2.8% loss over the past four weeks. Bausch + Lomb scored a strong price increase on investors’ optimism surrounding a Financial Times report stating that the company ...

Bausch + Lomb, one of the world’s largest contact lens ... Bausch Health’s market value has dropped to just $2.2bn as fears over its solvency grow and the company has become embroiled in ...

(Bloomberg) -- Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...